Clinical trials: Thyroid-Associated Ophthalmopathy
Graves Ophthalmopathy
Thyroid Treatment Trial
This project will compare the efficacy and safety of 2 methods of disease modification in the treatment of active moderate and severe thyroid orbitopathy.
- Trial name
- NCT00348413
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- Singapore National Eye Centre
Thyroid-Associated Ophthalmopathy
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
The purpose of this study is to determine whether injection of autologous fat or hyaluronic-acid injections in temporal region are effective in the treatment of temporal hollowing after lateral wall decompression in patients with…
- Trial name
- NCT02693808
- Testing
- Autologous fat injection, Hyaluronic acid injection
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Haukeland University Hospital
Thyroid Disease
Local Triamcinolone Injection in Active Thyroid Orbitopathy
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.
- Trial name
- NCT01280214
- Testing
- Triamcinolone
- Volunteers
- 30 people
- Sponsor
- HaEmek Medical Center, Israel
Graves Ophthalmopathy
Bimatoprost as a Treatment for Graves' Orbitopathy
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
- Trial name
- NCT03708627
- Testing
- Bimatoprost Ophthalmic
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease.
- Trial name
- NCT07400757
- Testing
- Atorvastatin (Lipitor), Vitamin D
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Thyroid Associated Ophthalmopathies
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152366
- Testing
- IBI311, Glucocorticoids
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen
Graves Disease, Graves Disease (Basedow's Disease)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves' disease is an autoimmune condition that causes an overactive thyroid. Some people with Graves' disease develop thyroid eye disease, also called Graves' orbitopathy, which can cause swelling around the eyes, eye…
- Conditions
- Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy
- Trial name
- ATORGO (NCT07883356)
- Testing
- Atorvastatin
- Where
- 7 sites in Sweden
- Volunteers
- 554 people
- Sponsor
- Region Skane
Gut Microbiota
Gut Microbiota is Associated With Autoimmune Thyroid Disease
Autoimmune thyroid disease (AITD), which includes Hashimoto's thyroiditis (HT) and Grave's disease (GD), are the most common organ-specific autoimmune diseases and affect more women than men, with a female-to-male ratio from 5 to…
- Trial name
- NCT03390582
- Testing
- Methimazole Pill
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Graves' Ophthalmopathy
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
The purpose of the study is to establish whether Bimatoprost eye drops are effective in reducing proptosis in inactive thyroid eye disease (TED) patients and improving quality of life in patients with TED.
- Trial name
- BIMA (NCT02059655)
- Testing
- Bimatoprost, Eye drop solution
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cardiff University
Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- STRIVE (NCT06384547)
- Testing
- Veligrotug
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 231 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED).
- Trial name
- NCT07265258
- Testing
- Teprotumumab N01, Methylprednisolone
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ophthalmopathy, Thyroid-Associated
Rituximab (RTX) Therapy in Patients With Active TAO
Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of…
- Trial name
- NCT02378298
- Testing
- Rituximab, Iv Methylprednisolone, peroral methylprednisolone and Methotrexate
- Where
- 5 sites in Sweden
- Volunteers
- 38 people
- Sponsor
- Göteborg University
Thyroid Associated Ophthalmopathy
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
The purpose of this study is to determine whether periorbital injection of glucocorticoid is effective and necessary in the treatment of mild TAO.
- Trial name
- NCT04548284
- Testing
- Glucocorticoids
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease, Graves' Orbitopathy
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or…
- Trial name
- EAP (NCT04040894)
- Testing
- Teprotumumab
- Where
- 8 sites in United States
- Sponsor
- Amgen
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment…
- Trial name
- NCT01868997
- Testing
- teprotumumab, normal saline
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 88 people
- Sponsor
- Amgen
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals